Table 3.
Associations between NVC and novel severe organ involvement/progression during follow-up (0–24 months)—univariable logistic regression
| Novel severe organ involvement and/or progression (0–24 months) | QUANTITATIVE ASSESSMENT |
QUALITATIVE ASSESSMENT |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capillary density |
Capillary dimension |
Capillary morphology |
Micro-haemorrhages |
Presence of scleroderma pattern |
Presence of ‘severe’ NVC patternsa |
|||||||
| OR | P-value | OR | P-value | OR | P-value | OR | P-value | OR | P-value | OR | P-value | |
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | |||||||
| Overall future organ involvement, (n = 257) | 0.76 (0.65, 0.88) | <0.001 | 1.25 (0.77, 2.01) | 0.372 | 1.33 (0.52, 3.13) | 0.533 | 1.01 (0.63, 1.62) | 0.955 | 1.34 (0.81, 2.21) | 0.251 | 2.136 (1.33, 3.44) | 0.002 |
| Peripheral vascular, (n = 111) | 0.68 (0.57, 0.80) | <0.001 | 1.15 (0.70, 1.92) | 0.585 | 0.58 (0.22, 1.54) | 0.271 | 0.72 (0.44, 1.16) | 0.170 | 1.26 (0.74, 2.18) | 0.399 | 1.82 (1.12, 2.98) | 0.015 |
| Pulmonary | ||||||||||||
| Structural | ||||||||||||
| New ILD, (n = 19) | 0.78 (0.56, 1.06) | 0.110 | 0.41 (0.16, 1.06) | 0.065 | 2.86 (0.37, 368.71) | 0.393 | 0.92 (0.36, 2.44) | 0.865 | 0.48 (0.19, 1.27) | 0.135 | 0.65 (0.25, 1.65) | 0.355 |
| Progression of known ILD, (n = 67) | 0.85 (0.70, 1.02) | 0.084 | 0.85 (0.48, 1.53) | 0.586 | 2.75 (0.76, 17.70) | 0.136 | 0.74 (0.42, 1.30) | 0.295 | 0.84 (0.46, 1.57) | 0.578 | 0.81 (0.47, 1.43) | 0.470 |
| Vascular | ||||||||||||
| New PH, (n = 45) | 0.87 (0.70, 1.07) | 0.201 | 0.60 (0.31, 1.15) | 0.122 | 1.54 (0.42, 9.94) | 0.552 | 0.42 (0.22, 0.80) | 0.008 | 0.88 (0.45, 1.83) | 0.728 | 1.46 (0.76, 2.93) | 0.260 |
| New PAH, (n = 5) | 0.82 (0.44, 1.46) | 0.521 | 1.90 (0.28, 37.34) | 0.547 | 0.77 (0.08, 102.11) | 0.864 | 0.95 (0.16, 7.33) | 0.959 | 2.26 (0.04, 22.71) | 0.365 | 3.01 (0.44, 59.17) | 0.283 |
| Skin progression, (n = 140) | 0.97 (0.83, 1.14) | 0.729 | 1.46 (0.86, 2.47) | 0.165 | 1.00 (0.232, 2.97) | 1.000 | 1.31 (0.78, 2.20) | 0.308 | 1.63 (0.93, 2.85) | 0.087 | 1.71 (1.02, 2.87) | 0.042 |
| Death, (n = 5) | 0.82 (0.43, 1.44) | 0.501 | 0.71 (0.12, 5.48) | 0.718 | 0.28 (0.04, 5.64) | 0.327 | 0.44 (0.06, 2.66) | 0.359 | 1.50 (0.22, 29.60) | 0.707 | 6.86 (0.72, 912.33) | 0.104 |
| Heart, (n = 18) | 0.98 (0.72, 1.33) | 0.917 | 0.818 (0.31, 2.30) | 0.692 | 0.50 (0.12, 3.36) | 0.417 | 1.31 (0.49, 3.89) | 0.595 | 1.02 (0.38, 3.12) | 0.969 | 1.01 (0.39, 2.75) | 0.977 |
| Gastrointestinal tract, (n = 5) | 1.56 (0.91, 2.72) | 0.106 | 1.92 (0.28, 37.75) | 0.540 | 0.76 (0.08, 101.70) | 0.862 | 0.45 (0.07, 2.36) | 0.339 | 1.49 (0.22, 29.33) | 0.714 | 0.18 (0.01, 1.26) | 0.088 |
| SRC, (n = 5) | 0.98 (0.54, 1.69) | 0.944 | 1.94 (0.28, 38.16) | 0.533 | 0.76 (0.08, 101.29) | 0.860 | 0.90 (0.17, 5.44) | 0.894 | 1.51 (0.22, 29.71) | 0.705 | 2.29 (0.42, 23.08) | 0.355 |
| Musculoskeletal, (n = 59) | 0.98 (0.82, 1.18) | 0.866 | 0.84 (0.47, 1.53) | 0.560 | 4.50 (0.90, 81.92) | 0.072 | 0.84 (0.47, 1.51) | 0.552 | 1.02 (0.55, 1.98) | 0.948 | 1.12 (0.63, 2.02) | 0.705 |
Underlined text: Firth log used. Bold text: Statistically significant finding (P < 0.05). a‘Active’ and ‘late’ NVC patterns were considered ‘severe’ NVC patterns. ILD: interstitial lung disease; NVC: nailfold videocapillaroscopy; OR: odds ratio; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; SRC: scleroderma renal crisis.